Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QURE | 144 | neutral | 3/10 | Two uniQure directors, David D. Meek and Jack Kaye, each filed Form 144 notices on June 11, 2026, signaling intent to se | Jun 11, 2026 |
| VREOF | 8-K | mixed | 5/10 | Vireo Growth Inc. closed the acquisition of Bridgewell Agribusiness LLC on June 5, 2026 for approximately $13.66 million | Jun 11, 2026 |
| ZLAB | INST-CLUSTER | bearish | 5/10 | Institutional cluster for ZLAB (Zai Lab) shows a bearish tilt with 4 sellers versus 1 buyer in Q3 2024. Two asset manage | Jun 11, 2026 |
| BKHA | S-4/A | bearish | 6/10 | Black Hawk Acquisition Corp filed Amendment No. 5 to its S-4 registration statement for the proposed business combinatio | Jun 11, 2026 |
| RFL | 8-K | mixed | 7/10 | Rafael Holdings reported Q3 fiscal 2026 financial results with minimal revenue ($179K) and a net loss of $4.2M ($0.08/sh | Jun 11, 2026 |
| ADIL | 8-K | bearish | 7/10 | Adial Pharmaceuticals (ADIL) has entered into and closed a definitive merger agreement to acquire Azora Therapeutics, a | Jun 11, 2026 |
| KRRO | INST-CLUSTER | neutral | 4/10 | A mixed institutional cluster in KRRO for Q3 2025 shows four buyers (led by Morgan Stanley doubling to $8.0M) adding $12 | Jun 11, 2026 |
| ESPR | INST-CLUSTER | mixed | 4/10 | Four institutional investors added $22.0M in ESPR positions during Q3 2025, led by Morgan Stanley and Nuveen doubling th | Jun 11, 2026 |
| ANNX | INST-CLUSTER | bullish | 5/10 | A bullish institutional cluster formed in ANNX during Q3 2025, with 5 buyers accumulating $9.8M in net new holdings vers | Jun 11, 2026 |
| FATE | INST-CLUSTER | bearish | 5/10 | FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M | Jun 11, 2026 |
| AUTL | INST-CLUSTER | bearish | 6/10 | A mixed institutional cluster in AUTL for Q3 2025 shows quant funds (Citadel, RenTech) and passive managers (Morgan Stan | Jun 11, 2026 |
| LXRX | INST-CLUSTER | neutral | 2/10 | A weak institutional cluster in LXRX shows 4 buyers (Schwab, Two Sigma, BofA, Morgan Stanley) adding $1.2M in aggregate | Jun 11, 2026 |
| VERA | INST-CLUSTER | bullish | 6/10 | Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M position and Citadel | Jun 11, 2026 |
| KYMR | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in Kymera Therapeutics for Q4 2025 shows 7 buyers adding $485.7M in net new positions, dom | Jun 11, 2026 |
| MGX | CLUSTER | neutral | 2/10 | Three insiders at Metagenomi, including the CFO, sold a total of ~$9K in open-market sales on June 5, 2026, at ~$1.30/sh | Jun 11, 2026 |
| TRVI | INST-CLUSTER | mixed | 5/10 | Four institutional buyers accumulated $90.6M in TRVI during Q4 2025, led by Fidelity ($51.2M add) and AllianceBernstein | Jun 11, 2026 |
| MGX | CLUSTER | neutral | 2/10 | Three insiders at Metagenomi Therapeutics, including the CFO, sold a total of $9K in open-market sales on June 5, 2026, | Jun 11, 2026 |
| ALTO | INST-CLUSTER | neutral | 3/10 | Four institutional investors increased positions in Alto Ingredients (ALTO) during Q4 2025, led by Two Sigma doubling to | Jun 11, 2026 |
| MIRM | INST-CLUSTER | bullish | 6/10 | A strong institutional buying cluster emerged in MIRM during Q4 2025, with 9 buyers adding $189.1M in net new positions | Jun 11, 2026 |
| EDIT | INST-CLUSTER | mixed | 5/10 | A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and Renaissance Technolo | Jun 11, 2026 |
| OCGN | INST-CLUSTER | bullish | 4/10 | A small institutional cluster has formed in OCGN shares for Q4 2025, with five funds (led by State Street, RenTech, and | Jun 11, 2026 |
| INBX | INST-CLUSTER | bullish | 6/10 | A strong institutional cluster formed in INBX during Q4 2025, with 10 buyers accumulating $172.5M in net new holdings ag | Jun 11, 2026 |
| ERAS | INST-CLUSTER | neutral | 3/10 | Four institutional investors, led by State Street and Morgan Stanley, added $20.7M in ERAS positions during Q4 2025, whi | Jun 11, 2026 |
| NKTR | INST-CLUSTER | mixed | 4/10 | In Q4 2025, four institutional buyers added $21.1M in NKTR positions (led by Point72 and Invesco doubling their stakes), | Jun 11, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab A/S filed a 6-K reporting a routine grant of 15,894 restricted stock units and 15,494 warrants to employees. The | Jun 11, 2026 |
| BNTC | INST-CLUSTER | neutral | 3/10 | Four institutional investors, primarily mega-passive managers, increased their BNTC positions in Q4 2025, with aggregate | Jun 11, 2026 |
| RGPX | 8-K | bearish | 7/10 | Regenerex Pharma filed an 8-K disclosing that it has commenced litigation against its former CFO, Kenneth W. Perry, alle | Jun 11, 2026 |
| MGX | CLUSTER | neutral | 2/10 | Three insiders at Metagenomi Therapeutics, including the CFO, sold a total of ~$9K in open-market sales on June 5, 2026. | Jun 11, 2026 |
| MGX | CLUSTER | neutral | 2/10 | Three insiders at Metagenomi Therapeutics (MGX) sold a total of $9K in open-market shares on June 5, 2026, representing | Jun 11, 2026 |
| NRIX | INST-CLUSTER | neutral | 4/10 | Eight institutional investors accumulated $278.7M in NRIX shares during Q4 2025, primarily through mega-passive index fu | Jun 11, 2026 |